Name | Number of supported studies | Average coverage | |
---|---|---|---|
GABAergic neuron | 3 studies | 30% ± 6% |
Insufficient scRNA-seq data for expression of NPAS1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
skin | 97% | 637.00 | 1759 / 1809 | 70% | 3.42 | 330 / 472 |
brain | 81% | 352.63 | 2148 / 2642 | 84% | 3.86 | 589 / 705 |
kidney | 81% | 87.45 | 72 / 89 | 52% | 1.31 | 473 / 901 |
thymus | 34% | 28.60 | 225 / 653 | 72% | 1.75 | 433 / 605 |
breast | 37% | 49.74 | 168 / 459 | 67% | 2.29 | 749 / 1118 |
ureter | 0% | 0 | 0 / 0 | 100% | 17.50 | 1 / 1 |
spleen | 99% | 214.69 | 239 / 241 | 0% | 0 | 0 / 0 |
stomach | 56% | 85.78 | 201 / 359 | 43% | 0.95 | 123 / 286 |
esophagus | 27% | 21.54 | 383 / 1445 | 72% | 2.03 | 132 / 183 |
lymph node | 0% | 0 | 0 / 0 | 97% | 5.72 | 28 / 29 |
lung | 23% | 16.80 | 133 / 578 | 65% | 1.87 | 755 / 1155 |
bladder | 29% | 23.86 | 6 / 21 | 55% | 1.49 | 277 / 504 |
pancreas | 7% | 4.85 | 23 / 328 | 75% | 2.05 | 133 / 178 |
tonsil | 0% | 0 | 0 / 0 | 78% | 2.13 | 35 / 45 |
uterus | 5% | 4.32 | 9 / 170 | 69% | 2.55 | 315 / 459 |
ovary | 4% | 4.52 | 7 / 180 | 66% | 1.52 | 285 / 430 |
blood vessel | 61% | 133.94 | 810 / 1335 | 0% | 0 | 0 / 0 |
adrenal gland | 19% | 13.88 | 48 / 258 | 34% | 1.32 | 79 / 230 |
intestine | 12% | 9.15 | 116 / 966 | 39% | 0.83 | 204 / 527 |
eye | 0% | 0 | 0 / 0 | 40% | 1.03 | 32 / 80 |
prostate | 20% | 15.24 | 49 / 245 | 19% | 0.30 | 97 / 502 |
liver | 11% | 17.66 | 25 / 226 | 26% | 0.72 | 105 / 406 |
heart | 31% | 29.80 | 270 / 861 | 0% | 0 | 0 / 0 |
adipose | 25% | 28.48 | 302 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 5% | 3.78 | 50 / 929 | 0% | 0 | 0 / 0 |
muscle | 0% | 0.33 | 4 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0001964 | Biological process | startle response |
GO_0042711 | Biological process | maternal behavior |
GO_0007417 | Biological process | central nervous system development |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0046982 | Molecular function | protein heterodimerization activity |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0003700 | Molecular function | DNA-binding transcription factor activity |
GO_0000977 | Molecular function | RNA polymerase II transcription regulatory region sequence-specific DNA binding |
Gene name | NPAS1 |
Protein name | Neuronal PAS domain-containing protein 1 (Neuronal PAS1) (Basic-helix-loop-helix-PAS protein MOP5) (Class E basic helix-loop-helix protein 11) (bHLHe11) (Member of PAS protein 5) (PAS domain-containing protein 5) Neuronal PAS domain protein 1 |
Synonyms | MOP5 PASD5 BHLHE11 |
Description | FUNCTION: May control regulatory pathways relevant to schizophrenia and to psychotic illness. May play a role in late central nervous system development by modulating EPO expression in response to cellular oxygen level (By similarity). Forms a heterodimer that binds core DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) leading to transcriptional repression on its target gene TH (By similarity). . |
Accessions | M0QX32 Q99742 M0R2M8 ENST00000594257.1 ENST00000602212.6 [Q99742-1] ENST00000449844.6 [Q99742-1] ENST00000439365.6 [Q99742-2] ENST00000594670.1 ENST00000602189.5 M0R1R8 |